A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

NCT02349295 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

363

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Placebo
DRUG: Ixekizumab 80 mg Q4W
DRUG: Ixekizumab 80 mg Q2W

Sponsor

Eli Lilly and Company